References
- Centers for Disease Control (CDC). Pneumocystis pneumonia—Los Angeles. Morb Mortal Wkly Rep. 1981;30(21):250–252
- Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding nature’s pathways. Immunol Rev. 2013;254:225–244.
- Pardi N, Hogan MJ, Porter FW. mRNA vaccines a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261–279.
- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
- Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586:567–571.
- Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020;383:1920–1931.
- Zhang P, Narayanan E, Liu Q, et al. A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nat Med. 2021;27:2234–2245.
- Mu Z, Wiehe K, Saunders KO, et al. mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Cell Rep. 2022;38:110514.
- Leggat DJ, Cohen KW, Willis JR, et al. Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science. 2022;378:eadd6502.
- International AIDS Vaccine Initiative. A phase 1 study to evaluate the safety and immunogenicity of eOD-GT8 60mer mRNA vaccine (mRNA-1644) in HIV-1 uninfected adults in good general health; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT05414786?term=mrna&cond=Hiv&draw=2&rank=3.
- International AIDS Vaccine Initiative. A phase 1 study to evaluate the safety and immunogenicity of eOD-GT8 60mer mRNA vaccine (mRNA-1644) and Core-g28v2 60mer mRNAVaccine (mRNA-1644v2-core); 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT05001373?term=mrna&cond=hiv&draw=2&rank=4.